CD133 Act as an Essential Marker in Ovarian Carcinogenesis

Document Type : Research Articles

Authors

1 Department of Anatomical Pathology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.

2 Department of Histology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia.

3 Department of Public Health, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.

4 Department of Anatomical Pathology, Faculty of Medicine, Universitas Muhammadiyah Makassar, Makassar, Indonesia.

5 Department of Anatomical Pathology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia.

Abstract

Objective: To analyze the role of cancer stem cells (CSC) in ovarian carcinogenesis through the identification of CD133 expression in the normal ovary (NO), serous cystadenoma (SC), borderline serous tumour (BST), low-grade serous carcinoma (LGSC), and high-grade serous carcinoma (HGSC). Materials and methods: A total of 48 tissue samples contain 5 NO, 10 SC, 5 BST, 8 LGSC, and 20 HGSC were stained with anti-CD133 antibody by immunohistochemical protocol. The difference in the H-score of CD133 expression between groups and their relationship to age, histomorphology, and localization was analyzed. Results: CD133 expression varied among tumor groups, with clinicopathologic parameters showing diverse associations (age p = 0.773; histomorphology p = 0.001; and localization p = 0.026). The comparison of CD133 H-scores differed significantly between each group (p = 0.0031), in which precursor and malignant lesions possessed more robust CD133 expression. Conclusion: The presence of CD133 cellular expression and localization in different types of serous ovarian tumours suggests that these markers are involved in ovarian tumorigenesis.

Keywords

Main Subjects